Announcements
- Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
- Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.5365 |
---|---|
High | 0.5365 |
Low | 0.5365 |
Bid | 0.5305 |
Offer | 0.5505 |
Previous close | 0.5365 |
Average volume | 1.11k |
---|---|
Shares outstanding | 108.57m |
Free float | 106.31m |
P/E (TTM) | -- |
Market cap | 62.04m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 07:08 BST.
More ▼